Zwar beobachteten Forschende unter anderem vereinzelt Effekte beim Sauerstoffverbrauch oder der Regeneration, der genaue Wirkmechanismus bleibt jedoch unklar
Diabetologia 45 , 195202 (2002)
Another limitation is that the protocol doesnt look for other blood glucose related markers like insulin and GLP-1
Emerging preclinical and pharmacogenomic evidence suggests that semaglutide suppresses dopamine release in the nucleus accumbens and blunts ventral tegmental area responses to rewarda mechanism that maps directly onto the anhedonia and amotivation dominating this patients presentation

NAD+ vs NMN vs NR (and IV vs SubQ) NAD+ Delivery Comparison Feature Mechanism NAD+ Injection (SubQ) Direct coenzyme delivery NAD+ Infusion (IV) Direct coenzyme delivery Oral NMN NAD+ precursor (converted in vivo) Oral NR (Niagen) NAD+ precursor (converted in vivo) Feature Typical research-planning dose NAD+ Injection (SubQ) 50-100 mg, 2-3x/week NAD+ Infusion (IV) 250-1,000 mg per session Oral NMN 300-600 mg/day Oral NR (Niagen) 300-1,000 mg/day Feature Speed to systemic NAD+ rise NAD+ Injection (SubQ) Hours NAD+ Infusion (IV) Minutes to hours Oral NMN Days to weeks Oral NR (Niagen) Days to weeks Feature Strongest human evidence NAD+ Injection (SubQ) Limited NAD+ Infusion (IV) Pilot PK and historical case reports Oral NMN Growing RCT base Oral NR (Niagen) Strongest RCT base Feature Convenience NAD+ Injection (SubQ) At-home injection technique required NAD+ Infusion (IV) Clinic visit, 2-4 hour infusion Oral NMN Daily oral capsule Oral NR (Niagen) Daily oral capsule Feature Regulatory status NAD+ Injection (SubQ) Not FDA-approved

Patients should avoid rubbing or massaging the injection site immediately after administration, as this may increase local irritation and potentially affect medication absorption